This site is intended for healthcare professionals
Drug news

Menarini acquires rights to Priligy for Premature Ejaculation treatment

Read time: 1 mins
Last updated:17th May 2012
Published:17th May 2012
Source: Pharmawand
Janssen Pharmaceutica and ALZA have returned the rights to the premature ejaculation treatment Priligy (dapoxetine) to Furiex Pharmaceuticals. FuriexPharmaceuticals has licensed to Menarini rights to commercialise Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex will retain development and commercialisation rights in the US, Japan and Canada. Priligy is marketed for on-demand treatment of premature ejaculation in 15 countries in Europe and elsewhere, and is approved for that indication in 43 countries. In January 2012, the CHMP, recommended the approval of Priligy in the remaining 20 EU countries, Norway and Iceland where the drug is not yet approved.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.